10 Cheap Pharmaceutical Stocks to Buy According to Analysts

6. Pfizer Inc. (NYSE:PFE)

Price Target Upside: 25.03% 

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets and sells biopharmaceutical products worldwide.  In developing and emerging markets, it promotes wellness, prevention, treatment, and cures. The company wants to become a leading cancer organization in the globe. With intentions to keep improving over the next ten years, it is currently the third-largest biopharma firm in the US for cancer.

With the addition of multiple new blockbuster medications to its portfolio as part of its 2030 targets, Pfizer Inc. (NYSE:PFE) is concentrating on its oncology pipeline for future growth. It is anticipated that the business will keep searching for chances to buy out promising pharmaceutical firms to expand its pipeline. It spent a large amount of its pandemic profits on the $43 billion purchase of the oncology-focused biotech business Seagen.

Pfizer Inc. (NYSE:PFE) is seeing good results from this approach, as management projects earnings growth of 10% to 18% in 2025. Additionally, analysts predict that over the next three to five years, the company’s earnings will increase by about 14% yearly. In addition, it offers a larger dividend yield than the majority of blue-chip companies, at an alluring 6.3%. Its management recently announced a 2.4% increase in its quarterly dividend in early December, reaffirming its intention to support and grow this dividend on a recurrent basis.